-+ 0.00%
-+ 0.00%
-+ 0.00%

Incyte Says EC Approves Opzelura Cream For Treatment Of Moderate Atopic Dermatitis In Adult Patients

Benzinga·07/29/2026 10:02:43
Listen to the news

The European Commission approval is based on Phase 3b TRuE‑AD4 data which demonstrated that Opzelura® (ruxolitinib) cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24, and was well tolerated 1,2,3

Incyte (NASDAQ:INCY) today announced that the European Commission (EC) has approved Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate.